These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38990434)

  • 21. A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
    Nogami N; Kubo T; Bessho A; Sakugawa M; Ikeo S; Yokoyama T; Seki N; Ochiai R; Fujimoto N; Murakami S; Kaira K; Harada T; Kishino D; Takiguchi Y; Shimokawa T; Kiura K; Yamashita N; Okamoto H
    Jpn J Clin Oncol; 2024 Jul; 54(7):805-812. PubMed ID: 38594880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].
    Zhao X; Wang M; Zhang L; Li L; Zhong W
    Zhongguo Fei Ai Za Zhi; 2012 Jan; 15(1):6-10. PubMed ID: 22237117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
    Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
    Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Yamasaki M; Murakami I; Nakano K; Doi M; Kitaguchi S; Kondo T; Sakurai J; Hattori N; Arita KI
    Anticancer Res; 2017 Feb; 37(2):923-928. PubMed ID: 28179353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
    Niho S; Kunitoh H; Nokihara H; Horai T; Ichinose Y; Hida T; Yamamoto N; Kawahara M; Shinkai T; Nakagawa K; Matsui K; Negoro S; Yokoyama A; Kudoh S; Kiura K; Mori K; Okamoto H; Sakai H; Takeda K; Yokota S; Saijo N; Fukuoka M;
    Lung Cancer; 2012 Jun; 76(3):362-7. PubMed ID: 22244743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.
    Chen Y; Kang S; Yan M
    Pharmacol Res Perspect; 2022 Jun; 10(3):e00941. PubMed ID: 35568997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
    Yamamoto N; Satouchi M; Doi T; Fujiwara Y; Yanagitani N; Kawa Y; Yoh K; Leopold L; Munteanu M; Sawada T; Han S; Noguchi K; Nishio M
    Invest New Drugs; 2024 Jun; 42(3):261-271. PubMed ID: 38530565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Argiris A; Lee JW; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL; Ramalingam SS; Schiller JH
    Ann Oncol; 2017 Dec; 28(12):3037-3043. PubMed ID: 28950351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
    Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
    Dhillon S; Syed YY
    Target Oncol; 2019 Dec; 14(6):759-768. PubMed ID: 31728860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
    Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
    Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
    Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
    Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
    BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
    Nakamura H; Satoh H; Kaburagi T; Nishimura Y; Shinohara Y; Inagaki M; Endo T; Saito T; Hayashihara K; Hizawa N; Kurishima K; Nawa T; Kagohashi K; Kishi K; Ishikawa H; Ichimura H; Hashimoto T; Sato Y; Sakai M; Kamiyama K; Matsumura T; Unoura K; Furukawa K
    Med Oncol; 2012 Dec; 29(5):3202-6. PubMed ID: 23117478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.